PREDICTIVE
BIOTECH
Revolutionary·Regenerative·Therapeutic

Product Snapshot

CoreCyte™
Cord Tissue Allograft Suspension

CoreCyte™ is a minimally manipulated human tissue allograft suspension, derived from the umbilical cord tissue layer of Wharton's Jelly, and processed to maximize mesenchymal stem cell (MSC) concentration.

CoreCyte™ MSCs have a much higher rate of proliferation when compared to MSCs derived from either adipose or bone marrow.[1]

CoreCyte™ can be used as a cost effective and pain free alternative to lipoaspirate and bone marrow aspirate procedures.

Potential Treatment Areas

- Aesthetics
- Back Pain
- Cartilage Damage
- Degenerated Joints
- Joint Dysfunction
- Knee Injuries
- Ligament Tears
- Meniscus Damage
- Muscle Tears
- Nerve Injury
- Rotator Cuff Injury
- Tendon Tears

Why use Predictive Biotech?

Predictive Biotech's innovative, minimally manipulated, allogeneic umbilical cord tissue therapies contain high levels of scaffolding proteins and regenerative molecules that your body needs to begin the healing process.

Our cellular tissue products, processed in our FDA registered lab, offer among the highest quality growth factors, cytokines, regenerative molecules and proteins to help the body recover, rebuild and renew.

CoreCyte™ is processed from donated human tissue from full term deliveries in accordance with FDA guidelines. CoreCyte™ is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act. CoreCyte™ is intended for homologous use.

CoreCyte™ Attributes

CoreCyte™ contains growth factors, cytokines and over one million viable MSCs (post thaw). CoreCyte™ is the only product on the market with verified MSC counts via third party testing and has demonstrated robust viability in laboratory testing. CoreCyte™ is supplied as a ready-to-use injectable allograft.

Advantages of CoreCyte™

1. CoreCyte™ does not require invasive procedures like bone marrow aspiration, or adipose tissue extraction, resulting in shorter procedure time, faster recovery and less pain.

2. Umbilical cord MSCs lack MHC-II and are therefore hypo-immunogenic.[2] Because MSCs are immune privileged, treatment with CoreCyte™ is unlikely to result in an allergic reaction for the recipient.



1. Sabapathy V, Sundaram B, VM S, Mankuzhy P, Kumar S (2014) Human Wharton's Jelly Mesenchymal Stem Cells Plasticity Augments Scar-Free Skin Wound Healing with Hair Growth. PLoS ONE 9(4): e93726. doi:10.1371/journal.pone.0093726

2. F Gao et.al. Mesenchymal stem cells and immunomodulation: current status and future prospects Cell Death and Disease (2016) 7, e2062; doi:10.1038/cddis.2015.327.

Recover. Rebuild. Renew.
www.predbiotech.com

2735 East Parleys way, Suite 205
Salt Lake City, Utah 8410
Tel: 1-888-408-9761
Fax: 1-801-487-24779

PBIO-DOC-PRODUCT-CC,V1,8/9/2017

PREDICTIVE BIOTECH

A PREDICTIVE TECHNOLOGY GROUP COMPANY

MEMORANDUM

Subject: Memo on File

From: Doug Schmid, PhD

Date: 01/15/2017

Re: Ohio State University Viability Study

---

3 samples of varying concentration were sent on dry ice, overnight via FedEx, to Ohio State University for viability testing. Using a dye similar to DAPI, cellular counts and viability were obtained on a Countess II cell counter. The data are as follows:

A. **Sample 1:** (our count was 2 million cells/mL)
   1.82 million total cell count per mL (average of 2 counts), 78% viability
B. **Sample 2:** (our count was 5 million cells/mL)
   4 million total cell count per mL (average of 2 counts), 73% viability
C. **Sample 3:** (our count was 500,000 cells/mL)
   555,000 total cell count per mL (average of 2 counts), 64% viability

In storing cells, cellular concentration is a key component of viability-if the cell density is too low (less than 1 million cells per mL) or too high (more than 10 million cells per mL), cellular viability upon thaw will be affected. These numbers can vary by cell type; some cell types can survive the freeze/thaw cycle better than others.

From these viability measurements (and others made in our lab), we have determined that the optimal freezing density for the CoreCyte™ product is 2 million cells/mL. This concentration consistently yields approximately 80% viability and at least 1 million cells/mL in the freshly thawed product. These numbers were again confirmed in-house.